Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,054
Total Claims
$2.3M
Drug Cost
1,127
Beneficiaries
$2,066
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+506%
Opioid rate vs peers
13.6% vs 2.2% avg
+46%
Cost per patient vs peers
$2,066 vs $1,411 avg
-29%
Brand preference vs peers
7.6% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid prescribing rate is 506% above the average for Internal Medicine providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
13.6%
Opioid Rate
1,636
Opioid Claims
$42K
Opioid Cost
4.9%
Long-Acting Rate
Brand vs Generic
Brand: 911 claims · $2.0M
Generic: 11,104 claims · $309K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Adalimumab | 43 | $486K |
| Etanercept | 11 | $198K |
| Tofacitinib Citrate | 33 | $193K |
| Adalimumab | 23 | $164K |
| Adalimumab | 13 | $93K |
| Ixekizumab | 13 | $92K |
| Certolizumab Pegol | 14 | $78K |
| Tofacitinib Citrate | 12 | $73K |
| Dapagliflozin Propanediol | 38 | $46K |
| Evolocumab | 32 | $39K |
| Semaglutide | 21 | $35K |
| Hydroxychloroquine Sulfate | 397 | $33K |
| Empagliflozin | 28 | $31K |
| Mirabegron | 40 | $31K |
| Milnacipran Hcl | 26 | $19K |
Prescribing Profile
Patient Profile
75
Avg Age
73%
Female
1.22
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About